Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Side-effects news

Show

From To
Maraviroc fails to match tenofovir/emtricitabine for first-line HIV treatment

An NRTI-sparing dual antiretroviral regimen containing maraviroc (Celsentri) plus ritonavir-boosted darunavir (Prezista) was found to be less effective than a standard combination with tenofovir/emtricitabine (the drugs in Truvada), according

Published
5 hours ago
By
Keith Alcorn
Drug that reduces abdominal fat in HIV patients also may reduce fat in liver

The only drug to receive Food and Drug Administration approval for reduction of the abdominal fat deposits that develop in some patients receiving antiviral therapy for HIV infection may also reduce the incidence of fatty liver disease in such patients. Massachusetts General Hospital investigators report that six months of daily injections of tesamorelin significantly reduced fat in the liver without affecting glucose metabolism.

Published
19 July 2014
From
Eurekalert Medicine & Health
Common HIV Drug May Boost Suicide Risk

A medication commonly used to treat HIV appears to double the risk that patients will develop suicidal thoughts or take their lives, new research contends. The finding concerns the anti-HIV drug efavirenz, which is marketed as Sustiva.

Published
02 July 2014
From
Web MD
Protease inhibitor therapy increases underlying genetic risk of diabetes for women with HIV

Treatment with an antiretroviral regimen based on a protease inhibitor magnifies any underlying genetic susceptibility to diabetes for women living with HIV, investigators report in the online edition

Published
01 July 2014
By
Michael Carter
Lowering toxicity of new HIV drugs predicted to improve life expectancy

While bringing new drugs to market is important for increasing life expectancy in younger people with HIV, lowering the toxicity of those drugs may have an even greater health impact on all HIV patients, a University of Pittsburgh Graduate School of Public Health analysis reveals.

Published
26 June 2014
From
EurekAlert
In HIV/TB coinfection, raltegravir may be an alternative to efavirenz

Patients coinfected with HIV and tuberculosis (TB) may benefit from raltegravir as an alternative to efavirenz, new research suggests.

Published
02 June 2014
From
Medscape
Risk score can help predict which people living with HIV have highest risk of kidney disease during tenofovir treatment

Investigators in the United States have developed a risk score to predict which people living with HIV have the highest risk of developing chronic kidney disease.

Published
31 March 2014
By
Michael Carter
Heart attack link to abacavir persists in D:A:D study

The nucleoside (NRTI) drug abacavir (Ziagen also in Kivexa/Epzicom) continues to be associated with a near-doubling of the risk of a heart attack, according to the latest

Published
14 March 2014
By
Gus Cairns
Raltegravir has the edge over two protease inhibitors in three-drug comparison study

In a head-to-head comparison of three drugs presented at the 21st Conference on Retroviruses and Opportunistic Infections (CROI) on Wednesday, the integrase inhibitor raltegravir (Isentress) proved to

Published
07 March 2014
By
Gus Cairns
ART use not linked to advanced kidney disease in 35,000 with HIV

Neither current nor recent use of tenofovir or any other antiretroviral therapy (ART) predicted advanced chronic kidney disease (CKD) or end-stage renal disease (ESRD) in a study or more than 35,000 adults with HIV infection.

Published
12 February 2014
From
International AIDS Society
← First12345...70Next →

Filter by country